[New targets in type 2 diabetes therapy].
The growing number of patients with type 2 diabetes stimulates the development of new antidiabetic drugs. New targets are addressed, as SGLT2 in the kidney or enzymes of glucose metabolism in the liver which might help to lower glucose levels and to overcome insulin resistance. The forthcoming years will show which of the drugs in clinical trials will get marketing authorization.